Kemp Dolliver
Director, Research & Senior Analyst Brookline Capital Markets
Kemp Dolliver is the Director of Research and a Senior Analyst at Brookline. Mr. Dolliver has extensive healthcare experience across multiple sell-side and buy-side roles in the U.S and Asia. Previously, he was the Founder and Chief Investment Officer of Cherrystone Hill Capital Management, LLC, which specialized in investing in listed healthcare companies throughout the world’s emerging markets. As a sell-side analyst, Mr. Dolliver was a Managing Director at Religare Capital Markets Pte. Ltd., Avondale Partners LLC, and Cowen Inc. His buy-side roles have included portfolio management positions at both Aetna and Bank of America. The Wall Street Journal has recognized him four times for his stock picking abilities in its “Best on the Street” survey.
Mr. Dolliver received a B.S. in Commerce from the McIntire School of Commerce, where he currently serves on the Advisory Board, and an M.B.A. from the Darden School of Business at the University of Virginia.
Seminars
Join leading investor and BD voices as they delve into the real risk–reward equation – from funding strategy and scaling RLTs to forging partnerships that accelerate patient access and ROI. Bring your questions and gain true insights into what it really takes to drive growth while mitigating risk in this rapidly evolving space.
- Evaluating economic challenges and opportunities in scaling RLTs from preclinical discovery to commercial launch
- Identifying strategies for securing ongoing investment despite supply chain and regulatory constraints
- Exploring collaborative models with manufacturers, regulators, and advocacy groups to accelerate patient access and return on investment
- Analyzing the interplay between regulatory uncertainty, clinical complexity, and investor risk perception
- Prioritizing scientific strategies that improve translational success and attract sustainable funding
- Demonstrating the value proposition of next-generation TRPs to stakeholders, including patient advocates, payers, and industry partners
